Clinical Trial: Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer
Study Status: Completed
Recruit Status: RECRUITING
Condition: Colon Adenocarcinoma
Study Type: INTERVENTIONAL
Official Title: Randomized Trial of Consolidation Targeted Adjuvant Therapy With Encorafenib and Cetuximab Versus Usual Care for Patients With Stage II/III BRAF V600E Colon Cancer
Brief Summary:
This phase II/III trial compares treatment with encorafenib and cetuximab to usual care (patient observation) for reducing the chance of cancer recurrence after standard surgery and chemotherapy in patients with BRAF-mutated stage IIB-III colon cancer.Encorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.Cetuximab is in a class of medications called monoclonal antibodies.It binds to a protein called EGFR, which is found on some types of tumor cells.This may help…
Read more